GlaxoSmithKline receives European approval for Kivexa.
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000627:therapeutic use*; D017277:Drug Approval; D004338:Drug Combinations; D005060:Europe; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D000099227:Abacavir